Adcetris 50mg


1 vial per box; Manufacturer: Takeda

Categories: , Tags: , ,


Composition Powder for concentrate for solution for infusion Brentuximab vedotin
Primary Use Treat classical Hodgkin lymphoma

Medicine Overview of Adcetris 50 mg


Uses of Adcetris 50 mg

  • Adcetris (Brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma
    (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior
    multi-agent chemotherapy regimens in patients who are not ASCT candidates.
  • Adcetris is indicated for treatment of patients with systemic anaplastic large cell lymphoma(sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

Adcetris 50 mg side effects

  • Peripheral neuropathy
  • Anaphylaxis and Infusion Reactions
  • Hematologic Toxicities
  • Serious Infections and Opportunistic Infections
  • Tumor Lysis Syndrome
  • Increased Toxicity in the Presence of Severe Renal Impairment
  • Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
  • Hepatotoxicity
  • Progressive Multifocal Leukoencephalopathy
  • Serious Dermatologic Reactions
  • Embryo-Fetal Toxicity

How to use Adcetris 50 mg

This medicine is given to you into a vein (intravenously) as an infusion. It is given by your doctor or
nurse over 30 minutes. Your doctor or nurse will also monitor you during and after the infusion.

How Adcetris 50 mg works

Adcetris contains the active substance brentuximab vedotin, an anti-cancer agent, which is made up
of a monoclonal antibody linked to a substance intended to kill cancer cells. This substance is
delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is a protein which
recognises certain cancer cells.

In Depth Information on Adcetris 50 mg

Expert advice for Adcetris 50 mg

  • The dose of this medicine depends on your body weight. The usual starting dose of Adcetris is
    1.8 mg/kg, given once every 3 weeks for no more than one year. Your doctor may lower your starting
    dose to 1.2 mg/kg if you have kidney or liver problems.
  • Adcetris is to be given to adults only. It is not for use in children.
  • When you first receive this medicine and during the course of treatment, tell your doctor if you:
    – have confusion, trouble thinking, memory loss, blurred or loss of vision, decreased strength,
    decreased control or sensation in one arm or leg, a change in the way of walking, or loss of
    balance, as these may be symptoms of a serious and potentially fatal brain condition known as
    progressive multifocal leukoencephalopathy (PML). If you have these symptoms prior to
    treatment with this medicine, tell your doctor immediately about any changes in these
    symptoms. You should also inform your partner or caregivers about your treatment, since they
    may notice symptoms that you are not aware of.
    – have severe and persistent stomach pain, with or without nausea and vomiting, as these may be
    symptoms of a serious and potentially fatal condition known as pancreatitis (inflammation of
    the pancreas).
    – have new or worsening shortness of breath or cough as these may be symptoms of a serious and
    potentially fatal lung complication (pulmonary toxicity)
    – are taking, or have previously taken, medicines which may affect your immune system, such as
    chemotherapy or immunosuppressive agents
    – have, or think you have, an infection. Some infections may be serious and can be due to
    viruses, bacteria, or other causes that may be life-threatening
    – experience a whistling sound during breathing (wheezing)/difficulty breathing, hives, itching,
    or swelling (signs of an infusion reaction).
    have any problems with a change in the sensitivity of the skin, especially in the hands or feet,
    such as numbness, tingling, a burning sensation, pain, discomfort or weakness (neuropathy)
    – have headaches, feel tired, experience dizziness, look pale (anaemia), or have unusual bleeding
    or bruising under the skin, longer than usual bleeding after your blood has been drawn, or
    bleeding from your gums (thrombocytopenia)
    – develop chills or shivering, or feel warm; you should take your temperature as you may have a
    fever. A fever with a low white blood cell count may be a sign of serious infection
    – experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of
    breath, or heart rhythm disturbances (this may be a potentially life-threatening complication
    known as tumour lysis syndrome)
    – experience flu-like symptoms followed by a painful red or purplish rash that spreads and
    blisters including extensive detachment of the skin that may be life-threatening (this may be a
    serious skin reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)
    – have new or worsening stomach pain, nausea, vomiting, constipation as these may be
    symptoms of a serious and potentially fatal stomach or intestinal complication (gastrointestinal
    – have abnormal liver test results as this may be related to a serious and potentially fatal liver
    injury (hepatotoxicity). Liver disease and other medical conditions that may have been present
    before you start taking Adcetris and some medications that you are currently taking might
    increase the risk of liver injury.
    – feel tired, have frequent urination, increased thirst, increased appetite with unintended weight
    loss, or irritability (hyperglycaemia)

Adcetris 50 mg related warnings

Special precautions for Adcetris 50 mg

Brentuximab vedotin should not be used during pregnancy unless the benefit to the mother outweighs the potential risks to the foetus. If a pregnant woman needs to be treated she should be clearly advised on the potential risk to the foetus.

There are no data as to whether brentuximab vedotin or its metabolites are excreted in human milk. A risk to the newborn/infant cannot be excluded. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from this therapy, taking into account a potential risk of breast-feeding for the child and the benefit of therapy for the woman.

Brentuximab vedotin may have a minor influence on the ability to drive and use machines.
Avoid the use of Adcetris in patients with severe renal impairment (CLcr <30 mL/min).
Avoid the use of Adcetris in patients with moderate or severe hepatic impairment.

What if you miss a dose of Adcetris 50 mg?

This is an intravenous infusion administered by your doctor or healthcare professional.